- Phase 1b study evaluates pasritamig with docetaxel in metastatic castration-resistant prostate cancer.
- Pasritamig targets KLK2, a prostate cancer-specific marker, minimizing effects on healthy tissue.
- The study supports advancement to Phase 3 trials with promising safety and efficacy results.
Study Overview
Johnson & Johnson announced preliminary results from a Phase 1b study evaluating pasritamig, a bispecific T-cell engaging antibody, in combination with docetaxel for metastatic castration-resistant prostate cancer. The study was presented at the 2026 ASCO Genitourinary Cancers Symposium.
Mechanism of Action
Pasritamig is designed to engage the immune system by binding CD3 on T cells and human kallikrein 2 (KLK2), a prostate cancer-specific target. This approach focuses immune activity on prostate cancer cells, potentially limiting effects on healthy tissue.
Safety and Efficacy
The combination showed a safety profile consistent with docetaxel alone, with no new safety signals. Clinically meaningful efficacy was observed, including high rates of prostate-specific antigen (PSA) responses and sustained PSA reductions.
Future Development
The promising results support the continued development of pasritamig into Phase 3 studies, with the potential to improve outcomes for patients with advanced prostate cancer.
